Gilead To Become Victim Of Own Success In Japan?
This article was originally published in PharmAsia News
Executive Summary
Gilead Sciences is on a roll both globally and in Japan, where two of its key drugs for hepatitis C have been launched this year and the California-based company is planning to roll out other pipeline products, including in oncology. But the rapid sales growth for its HCV products is raising the specter of possible price cuts.